In:
The Prostate, Wiley, Vol. 73, No. 5 ( 2013-04), p. 531-541
Kurzfassung:
The androgen receptor (AR) is a main therapeutic target for treatment of prostate cancer (PCa). The natural compound isochaihulactone (K8), which has a chiral center ring and two racemic forms ( E ‐K8 and Z ‐K8), has anti‐tumor effects on multiple cancer types both in vitro and in vivo. Here, we determined which form of K8 contains significant tumor cytotoxicity and examined how this form regulates AR expression in PCa cells and xenografts. METHODS We chose the androgen‐dependent human PCa cell line LNCaP and the androgen‐independent cell lines DU145 and PC‐3 to study the anti‐tumor potency and AR regulation mediated by Z ‐K8. We measured cell viability and used flow cytometry, RT‐PCR, and Western blotting. Growth inhibition in vivo was evaluated with an LNCaP xenograft animal model. RESULTS In LNCaP cells, Z ‐K8 significantly repressed cell proliferation, induced apoptosis, repressed AR mRNA and protein expression in a time‐dependent manner, and induced JNK phosphorylation. Furthermore, treatment with a JNK inhibitor significantly abolished Z ‐K8‐induced AR downregulation. Z ‐K8 did not significantly inhibit reporter gene expression of constructs containing the AR promoter when it contained a mutated Sp1 binding site. Z ‐K8 also showed anti‐tumor effects in the xenograft animal model. CONCLUSION Z ‐K8 not only induced LNCaP apoptosis but also reduced AR expression. These results indicate that Z ‐K8 may be a potential anti‐tumor drug for PCa therapy. Prostate 73: 531–541, 2013. © 2012 Wiley Periodicals, Inc.
Materialart:
Online-Ressource
ISSN:
0270-4137
,
1097-0045
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2013
ZDB Id:
1494709-2
